Advertisement
Advertisement
U.S. markets closed
Advertisement
Advertisement
Advertisement
Advertisement

23andMe Holding Co. (ME)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
2.5100+0.0900 (+3.72%)
At close: 04:00PM EST
2.5300 +0.02 (+0.80%)
After hours: 07:42PM EST
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Commodity Channel Index

Commodity Channel Index

Previous Close2.4200
Open2.4000
Bid2.5100 x 3000
Ask2.5200 x 2200
Day's Range2.4000 - 2.5200
52 Week Range2.0200 - 6.3100
Volume1,587,152
Avg. Volume2,672,758
Market Cap1.143B
Beta (5Y Monthly)1.36
PE Ratio (TTM)N/A
EPS (TTM)-0.6020
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est5.69
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued

Subscribe to Yahoo Finance Plus to view Fair Value for ME

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • 23andMe Holding Co.
    Analyst Report: 23andMe Holding Co.23andMe is a consumer-facing healthcare technology company, primarily involved in the sale of direct-to-consumer personal genome services, or PGS, through DNA collection kits shipped via mail. The company provides users access to reports summarizing estimated genetic ancestry breakdown, phenotypic trait reports, and various health predisposition and disease carrier reports. More than 80% of 23andMe customers voluntarily elect to share their de-identified genetic data with the company, which is used to develop future reports. In 2018, GlaxoSmithKline made an equity investment in the company, entering a five-year collaborative agreement with 23andMe to develop drug candidates.
    Rating
    Fair Value
    Economic Moat
    7 months agoMorningstar
View more
  • GlobeNewswire

    23andMe to Report FY2023 Third Quarter Financial Results

    SOUTH SAN FRANCISCO, Calif., Jan. 26, 2023 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (Nasdaq: ME) (23andMe), a leading human genetics and biopharmaceutical company with a mission to help people access, understand, and benefit from the human genome, announced today that it will report financial results for the fiscal year 2023 (FY2023) third quarter after the market closes on Wednesday, February 8, 2023. The Company will webcast a conference call at 4:30 p.m. Eastern Time on that date to discuss th

  • Motley Fool

    3 Penny Stocks That Could Make You Filthy Rich

    The current economic environment, however, has pushed several intriguing, innovation-oriented companies into penny stock territory. Although these names are still exceedingly high-risk, I think aggressive investors may want to consider buying shares of Precigen (NASDAQ: PGEN), Rigel Pharmaceuticals (NASDAQ: RIGL), and 23andMe Holding Company (NASDAQ: ME) right now. Read on to find out why these three low-priced equities might be a tremendous wealth escalator for patient shareholders.

  • Simply Wall St.

    Institutional investors own a significant stake of 37% in 23andMe Holding Co. (NASDAQ:ME)

    If you want to know who really controls 23andMe Holding Co. ( NASDAQ:ME ), then you'll have to look at the makeup of...

Advertisement
Advertisement